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NAC Non-amyloid-β component 
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Abstract: The link between protein aggregation and neurodegenerative disease is well 
established. However, given the heterogeneity of species formed during the aggregation 
process, it is difficult to delineate details of the molecular events involved in generating 
pathological aggregates from those producing soluble monomers. As aberrant aggregates 
are possible pharmacological targets for the treatment of neurodegenerative diseases, the 
need to observe and characterise soluble oligomers has pushed traditional biophysical 
techniques to their limits, leading to the development of a plethora of new tools capable of 
detecting soluble oligomers with high precision and specificity. In this review, we discuss a 
range of modern biophysical techniques that have been developed to study protein 
aggregation, and give an overview of how they have been used to understand, in detail, the 
aberrant aggregation of amyloidogenic proteins associated with the two most common 
neurodegenerative disorders, Alzheimer’s disease and Parkinson’s disease. 
1. Introduction 
Finding an effective therapy for neurodegenerative diseases is one of the most pressing 
issues in society. The difficulty of this task is partially due to the lack of a precise 
understanding of the mechanisms underpinning the diseases. Common neurodegenerative 
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disorders are characterised by progressive neuronal cell loss and the presence of protein 
aggregates in the affected and surrounding areas of the brain [1–4]. In the context of 
research into neurodegenerative diseases, the association of these disorders with the 
aggregation of a specific protein is a relatively recent advance. Whilst the two most common 
dementias, Alzheimer’s disease (AD) and Parkinson’s disease (PD) were first described 
more than a century ago [5] [6], it took more than 75 years to identify the main components 
of the deposits found in these diseases: in 1985, the peptide amyloid-β (Aβ) was identified 
as main component of the extracellular plaques found in AD [7] and shortly thereafter 
neurofibrillary tangles (NFTs) were shown to primarily consist of the microtubule associated 
protein tau [8–11]. Subsequently, α-synuclein (αS) was identified as main component of 
Lewy bodies typically present in PD brains [12]. These pivotal discoveries have sparked a 
vast amount of studies on the role of these proteins on the pathogenesis of AD and PD and 
other neurodegenerative diseases. However, it has only been more recently that protein 
aggregation has been studied in great detail on a molecular level. 
Whilst the protein deposits found in AD and PD are thought of as archetypical amyloids, 
protein aggregation has been described as a general property of the polypeptide chain 
[13,14]. Typically, the aggregation process starts as a consequence of protein misfolding; a 
protein loses its native conformation and acquires one that is able to self-interact. The 
process is facilitated in the case of intrinsically disordered proteins, such as Aβ and αS, as 
their folding energy landscape makes them inherently prone to explore different 
conformations. Once a nucleus is formed, the aggregates can grow through monomer 
addition, and further secondary processes can occur to form additional nuclei. For example, 
secondary nucleation and fibril fragmentation processes have been included in a 
mathematical model describing protein aggregation to more accurately fit the available data 
[15–17]. Fragmentation describes the ability of fibrils to break apart and form additional fibrils 
which can themselves grow and fragment further. Secondary nucleation introduces the 
possibility that fibrils can recruit monomers to their surface and act as additional nuclei for 
the growth of other fibrils. Both of these processes may lead to an exponential increase in 
fibril mass, which may account for disease spreading and progression in the brain.  
Although much of our knowledge of protein aggregation has come from in vitro studies, 
fibrils found in vivo tend to be morphologically indistinguishable from those formed in the 
test-tube [18,19]. These in vitro studies have made use of recombinant proteins that are 
incubated under conditions favouring their aggregation, which can vary greatly depending on 
the protein [20–30]. The resultant aggregation kinetics can then be measured and are 
usually separated into three main phases: the lag phase, the elongation phase and the final 
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plateau [31]. These phases are identified as such based on observations made from 
quantifying protein aggregation using bulk techniques, rather than discrete microscopic 
steps, and are believed to be shared by all amyloid-forming proteins. The nucleation phase 
is the name ascribed to the period of time between the initiation of aggregation and the 
formation of detectable protein aggregates. This phase is the start of amyloid formation, and 
as mentioned above, necessarily begins with the formation of seeding-competent 
aggregation nuclei. The elongation phase refers to the period of time where the length of 
aggregates increases. On the microscopic level, along with continued nucleation, the 
aggregates grow and associate to form mature amyloid fibrils. The final plateau phase is 
characterised by the detectable aggregates reaching a dynamic equilibrium with each other 
and monomeric proteins. 
Despite the complications arising from their insolubility and high molecular weights, amyloid 
fibrils were the first aggregate species described [32]. However, much evidence points 
towards the earliest species as being the most toxic [33–41]. Unfortunately, these species 
are highly heterogeneous, rare and transient in nature, and so are difficult to study using 
traditional biochemical techniques. For this reason, many modern techniques have been 
developed and adapted to study the aggregates formed in this step of the fibril-formation 
process. This review describes some of these methods, and goes on to explain how they 
have led to key findings in the aggregation of the proteins associated with PD and AD, the 
most common neurodegenerative diseases. 
2. Overview of techniques  
a) Bulk techniques 
Fluorescence 
Historically, the kinetics of in vitro fibril-formation have been followed using optical methods. 
One of the most common techniques makes use of the benzothiazole salt, thioflavin-T (ThT) 
[42]. Upon binding to β-sheet rich structures, such as amyloid fibrils, the fluorescence 
quantum yield of ThT increases by several orders of magnitude [43], therefore allowing the 
quantification of fibril formation (Figure 1a). The dye can be added to time-points taken from 
an aggregation reaction, and its fluorescence measured in a conventional fluorimeter (ex 
situ). Alternatively, it can be added to a solution of aggregating protein in situ and the 
fluorescence increase can be measured continuously with a plate-reader. However, care 
must be taken to ensure that the dye itself does not affect the aggregation process. The 
advantage of this method is that it is simple to implement, requiring inexpensive equipment, 
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and little training. Much work has also focused on fitting mathematical models to the 
resultant fluorescence traces to gain insights into the kinetics involved in the fibril-formation 
process, such as determining the relative contributions of primary nucleation, elongation, 
secondary nucleation and fragmentation [44–46]. However, such optical techniques only 
observe the ensemble fluorescence from the system, and so limited information on the 
individual species contributing to this enhanced fluorescence is obtained. Moreover, not all 
aggregates bind ThT, meaning some species important to disease pathology may be missed 
[21]. For this reason, a range of new dyes have been developed, some of which can detect a 
wider range of aggregates [47,48].  
Dynamic light scattering (DLS) 
Whereas bulk optical methods enable the total relative β-sheet mass of a sample to be 
measured over time, other methods offer insights into the actual sizes of the species 
present. DLS the scattering of laser light by small insoluble particles to gain information on 
the size distribution of a sample. This method is often used in the study of protein 
aggregates [49], and allows information to be obtained on the size of the aggregates (Figure 
1b). Once again, it has the advantage of being simple to implement and no potentially 
interfering dye or chemical is required. However, DLS provides the average size of the 
species present rather than the sizes of the individual aggregates. The technique is also 
biased towards larger species, which have a greater propensity to scatter light. Additionally, 
DLS has a practical resolution limit of approximately 1 nm which is imposed by factors such 
as sample purity and the wavelength of the laser being used. 
Circular dichroism (CD) 
In addition to the size distribution of aggregating species, the average protein structure can 
also be measured using techniques such as CD. CD exploits the ability of regular amino acid 
structures within proteins to rotate the polarisation of light to provide information on the 
secondary and tertiary structures of proteins. This is useful for studying protein aggregation, 
since many of the proteins that aggregate are intrinsically disordered in their native state, 
and so have very little distinct secondary or tertiary structure; however, when forming 
amyloid structures, the β-sheet content increases, and measuring this can provide structural 
insights into the fibril formation process (Figure 1c) [50].  
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b) Surface-based techniques: 
Quartz crystal microbalance 
To overcome some of the shortfalls of ensemble techniques, surface-based methods have 
also been used to characterise the aggregation process. Quartz crystal microbalance (QCM) 
sensors are able to determine mass variation per unit area by measuring the change in 
frequency of a resonating quartz crystal. This method is sensitive enough to report on the 
change in mass of surface-attached fibrils and has enabled very precise measurements of 
the influence of solution conditions on αS fibril elongation to be obtained [52].  
Atomic Force Microscopy 
Atomic force microscopy (AFM) enables the surface topography of a sample to be deduced 
as a cantilever and tip raster scans a surface [53]. A laser beam reflected from the tip is 
detected by a photodiode detector, enabling the topography of the sample to be mapped 
with a vertical resolution of less than 1 nm, although the horizontal resolution is lower. These 
techniques have the advantage of being label-free, and in the case of AFM, allow individual 
aggregates to be observed. However, they are sensitive to surface effects which may 
perturb the findings [54]; for example, fibrils may grow at different rates on the surface, and 
some species may have a greater propensity to adsorb on the surface than others.  
c) Fluorescence based single-molecule techniques 
The protein aggregation process leads to the generation of a wide range of species, from 
highly heterogeneous oligomers, through to amyloid fibrils, which have a well-defined 
structure. For this reason, the ability to characterise individual aggregates using single-
molecule fluorescence methodologies has revealed much about protein aggregation. To 
visualise individual molecules, the signal-to-noise ratio must be high, and one way in which 
this is achieved is through the reduction in the excitation volume. There are two principal 
methods by which this is brought about: confocal microscopy and total internal reflection 
fluorescence (TIRF) microscopy.  
 
Confocal microscopy techniques 
In single-molecule confocal microscopy, a collimated laser beam is focused by a high 
numerical aperture objective lens to a diffraction limited spot (< 1 µm). As individual dye-
tagged molecules are excited in the confocal volume, their fluorescence emission is 
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collected by the same objective lens, filtered, and passed through a pinhole (to reject out of 
focus light) and focused onto a highly sensitive avalanche photodiode detector (Figure 2a). 
Confocal microscopy was first used in this way to study the aggregation of the SH3 domain 
of phosphatidylinositiol-3'-kinase (PI3-SH3) [55]. In this study, equimolar mixtures of two 
different dye-labelled PI3-SH3 solutions were incubated under conditions favouring protein 
aggregation, and regular samples were collected to be analysed using two color coincidence 
detection (TCCD). With TCCD, two confocal volumes of different wavelengths are 
overlapped, in this case 488 nm (blue) and 633 nm (red). As dye-tagged molecules 
transverse the overlapped volumes, they generate bursts of fluorescence. Monomeric PI3-
SH3 only gave rise to a signal in either the blue-excitation, or red-excitation channel, 
whereas the oligomers generated a coincident signal in both channels if they contained both 
dyes (Figure 3a). This method therefore provided the means to separate oligomeric events 
from monomers and the total intensity provided information about the sizes of the oligomers. 
In a similar technique, scanning for intensely fluorescent targets (SIFT) [56,57], the two 
overlapped laser beams are scanned through the sample to detect species. 
In some cases, the different colour dye molecules in the oligomers formed are close enough 
for Förster resonance energy transfer (FRET) to occur between them. This allows for the 
use of one-color excitation (to excite the donor fluorophores), and emission in the acceptor 
channel denotes the presence of an oligomer (Figure 3b). This has been used to study the 
aggregation of a variety of proteins as the FRET efficiency can be used to determine the 
relative mean distance between the fluorophores, giving some insights into the monomer 
density within an aggregate [35,58,59]. Surface effects are removed in solution-based 
confocal microscopy; however, data interpretation is more complex, since structures must be 
inferred from bursts of fluorescence. Additionally, the low concentrations (sub-nanomolar) 
required for single-molecule confocal measurements may mean that many species 
dissociate upon dilution, and so are not observed. However, microfluidic devices to rapidly 
dilute samples before complexes have had the chance to dissociate have been designed, 
and these could go some way to remedying this potential problem [60]. 
In contrast to discrete burst analysis, a confocal microscope setup can also be used to 
perform fluorescence correlation spectroscopy (FCS) [61,62]. FCS relies on measuring 
temporal fluorescence fluctuations as multiple fluorophores occupy the confocal volume 
(concentrations of 1-100 nM). The careful analysis of such fluctuations through 
autocorrelation and fitting to relevant diffusion equations enables the determination of 
concentrations and diffusion coefficients. However, the method does not strictly observe 
individual molecules, and deconvolution of multiple populations can be troublesome.  
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Total internal reflection fluorescence (TIRF) microscopy techniques 
In contrast to confocal microscopy, TIRF microscopy is usually a surface-based method. 
Total internal reflection occurs when a plane of light travelling through a transparent medium 
of a given refractive index is incident upon a dielectric interface with another medium of a 
lower refractive index at an angle greater than the critical angle. Despite being called total 
internal reflection, an electromagnetic wave termed the “evanescent wave” penetrates a 
small distance into the second low refractive index medium, and this decays exponentially 
away from the interface. In objective-based TIRF microscopy [63], collimated laser light from 
a high numerical aperture objective lens is reflected from the bottom of a glass coverslip 
containing aqueous solution, and the evanescent wave is used to excite a wide field typically 
<200 nm into the sample (Figure 2b). The fluorescence is then collected by the same 
objective, filtered and focused onto either an electron-multiplying charge-coupled device 
(EMCCD), or a scientific complementary metal-oxide-semiconductor (sCMOS) camera. TIRF 
microscopy can be used to directly visualise individual labelled aggregates immobilised on a 
glass slide, allowing their physical size and structure to be imaged, down to a resolution of 
around 250 nm (the diffraction limit of visible light). The number of monomers present in an 
oligomer can be estimated using this method. As individual dye molecules within the 
oligomers photobleach, there is a stepwise decrease in the total intensity of each individual 
spot, and these can be counted to determine how many dye molecules were present in the 
oligomer. This becomes problematic if there are too many dye molecules present, but this 
can be avoided using sub-stoichiometric labelling [64].  
In the above described methods, the protein-of-interest must be labelled with an organic 
fluorophore; however, this can be challenging, and in some cases may affect the kinetics of 
protein aggregation, or structures of the fibrils [65]. An alternative method uses dyes such as 
ThT coupled with TIRF microscopy to detect the protein aggregates. This has the advantage 
of not needing to have the dyes directly conjugated to the protein, and means that the 
method can be used to observe oligomers within biofluids such as cerebrospinal fluid [51]. 
However, the binding mechanism of such dyes is not fully understood. They may not bind to 
all aggregates, and could also bind other structures unrelated to amyloid.  
d) Super-resolution microscopy 
The diffraction of light limits optical microscopy to a resolution of around 250 nm. However, 
super-resolution methods [66–68] have enabled optical imaging at much higher resolutions, 
allowing structures as small as 5 nm to be characterised [69]. There are two main strategies 
permitting super-resolution microscopy to be performed. One approach, implemented on a 
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scanning confocal microscope, termed stimulated emission depletion (STED) microscopy, 
limits the illumination of the sample to regions smaller than the diffraction limit [68]. The 
other strategy works by stochastically separating single fluorophores in time to gain 
resolution in space (stochastic switching and readout), and this can be done by various 
methods. Stochastic optical reconstruction microscopy (STORM) [67] relies on dyes 
stochastically photoswitching between dark and fluorescent states, allowing subpopulations 
to be localised individually. Photoactivated localisation microscopy (PALM) [66] uses 
photoswitchable fluorescent proteins (usually switched to a longer wavelength through 
irradiation with ultraviolet light) to separate fluorescence from single emitters in time. Other 
methods, such as point accumulation for imaging in nanoscale topography (PAINT) [70] and 
uniform PAINT (uPAINT) [71] rely on fluorescent molecules temporarily binding to surfaces, 
where they are localised to build up a super-resolved image. In adapted versions of this 
various methods of achieving transient binding have been described, including using short 
DNA sequences (DNA-PAINT) [72,73]. Additionally, a technique termed spectrally-resolved 
PAINT (sPAINT) [74] uses the transient binding of the dye nile red to characterise the 
surface hydrophobicity of protein aggregates. The emission wavelength of nile red varies 
depending on the hydrophobicity of its environment, and so by detecting the wavelength in 
addition to the location of nile red binding events, hydrophobicity can be mapped at the 
nanoscale.  
e) Higher resolution  
Although super-resolution techniques can now readily achieve imaging with a resolution of 
greater than 20 nm, this is sometimes not sufficient to fully characterise the smallest of 
oligomers. Higher resolution methods are routinely used to determine the structure of protein 
aggregates. Transmission electron microscopy (TEM) uses a tightly focused beam of 
electrons to image the specimen as they pass through it, and gives rise to a resolution as 
high as 0.2 nm. Sample preparation for TEM is complex, and this limits its usefulness for 
looking at some structures. Notably, the Nobel prize in Chemistry has recently been 
awarded to the developers of cryo-electron microscopy (cryo-EM) [75,76]. In this technique, 
the sample does not have to be chemically fixed, but is instead rapidly cooled to cryogenic 
temperatures, meaning that the protein can be observed in its native state. However, the 
generation of a three-dimensional structure of proteins from cryo-EM relies on reconstructing 
images from many different projections, and this is challenging for highly heterogeneous 
specimens, such as oligomers. Nevertheless, it has been used to characterise the structure 
of purified kinetically trapped oligomers of αS [77], tau filaments extracted from a human AD 
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brain sample [78], poly-glutamine expanded huntingtin fibrils from cultured neurons [18], and 
Aβ fibrils [79]. 
3. Alzheimer’s disease and the visualisation of amyloid beta aggregates 
The presence of extracellular plaques composed of the Aβ peptide is a pathological hallmark 
of AD [7].  Aβ is formed and released into the extracellular space through the cleavage of the 
amyloid precursor protein (APP) [80]. This cleavage can be performed by several proteases 
such as ADAM 10, BACE 1, α- and γ-secretase, leading to the formation of various N- and 
C-terminal isoforms of Aβ exist [81,82]. When the expression and degradation of Aβ is 
controlled there is evidence suggesting that the peptide has several important and possibly 
neuroprotective functions, such as regulating synapse activity [83]. However, when the 
homeostatic balance of Aβ production is disturbed the aggregation of the peptide plays a key 
role in neurodegeneration [84–86]. As a result, much effort has been dedicated to 
characterising aggregated Aβ species. It is not clear precisely which factors lead to the loss 
of the normal balance, however the ratio of the most abundant cleavage products Aβ1-40 
and Aβ1-42 has been implicated to be important to AD pathogenesis, adding greater 
complexity to the oligomer formation process  [87]. 
Due to the high aggregation propensity of Aβ, it can be challenging to obtain a 
homogeneous monomeric sample, as the molarities required for many ensemble methods 
are high enough to trigger aggregation. This makes studying the kinetics of aggregation 
troublesome, since there may already be seeds present which can complicate the reaction. 
Despite this, a variety of soluble aggregates have been studied, but most have not been 
characterised beyond the use of SDS-PAGE and antibody reactivity[88]. Beyond this, 
various structural and functional details have been obtained for water-soluble, non-fibrillar 
Aβ assemblies [88]. Structures that have been described include protofibrils [89,90], Aβ-
derived diffusible ligands [91,92], globulomers [93], spheroids [94,95], disulphide cross-
linked Aβ [27], cell-derived SDS-stable low n-oligomers [96,97], Aβ*56 [98] and a brain-
derived SDS-stable Aβ-dimer [27],[88]. They all have in common distinctly different biological 
effects compared with mature fibrils, although some of them contain cross β-sheet 
structures, such as the protofibrils [89,90]. 
The most commonly used techniques to characterise Aβ aggregates are AFM and TEM. 
Both techniques are used to examine the morphological differences exhibited by various 
aggregates, such as elongated amyloid fibrils and small, globular oligomers [99–102]. These 
approaches have been used to study all species throughout the aggregation process, as 
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well as comparing the structure of aggregates produced by mutant variants [103,104]. AFM 
studies showed that not only the morphology of aggregates changed throughout the 
aggregation process, but the Young’s modulus (a measure of stiffness) also increased, 
suggesting an internal structural rearrangement [105]. Furthermore, Aβ fibrils have been 
resolved at the atomic level with X-ray crystallography and solid state-NMR including 
variations in clinical subtypes of AD [106–108]. Structures of the cross β-sheet amyloid state 
are reviewed in great detail by Eisenberg and Jucker [109]. A complete de novo 42 amino 
acid atomic model of Aβ fibrils has also recently been solved via cryo-EM [110].  
Fluorescently labelled Aβ peptide variants are readily available as solid-phase synthesis 
allows the efficient site-specific conjugation of single fluorescent tags to the Aβ peptides. 
This has facilitated the use of highly sensitive single-molecule methods to study the 
properties of individual Aβ aggregates, especially oligomers. The application of single-
molecule methods to study early aggregates has provided insights into the size distributions 
and effects of very early aggregates [111–113]. Narayan and colleagues found that Aβ 
oligomers initiated neuronal damage on astrocytes [114] and were sequestered by an 
extracellular chaperone [112]. They described the oligomers as mostly below 10-mers in 
monomer units, and using TCCD it was possible to study these at levels much closer to their 
physiological concentrations compared to other techniques [115]. Furthermore, these 
fluorescent methods have been used to show how oligomers preferentially interact with cell 
membranes relative to monomers [116]. Subsequently, Flagmeier et al. used an 
ultrasensitive membrane disruption assay to show that Aβ42 oligomers but not monomers or 
fibrils are able to disrupt lipid vesicles at picomolar concentrations [86]. 
Aggregate analysis via TCCD and confocal photobleaching trajectory analysis [117] are 
limited by acquisition times and instrumental dead times. Whilst the timescale of in vitro 
aggregation of the majority of amyloidogenic proteins is sufficiently slow to take full 
advantage of these techniques, the temporal resolution can be a limiting factor for the ability 
to detect early aggregation events of proteins with fast aggregation kinetics, such as Aβ42. 
To overcome this limitation, microfluidic strategies have been used, whereby the 
aggregation mixture is rapidly flowed through the confocal volume to increase the rate of 
detection, and therefore increase the time-resolution of the methods [58].  
TCCD measurements of co-oligomer formation between Aβ40 and Aβ42 helped generate a 
thermodynamic model of the peptides’ aggregation propensities [118]. It should be noted 
that the ability to size aggregates from TCCD and smFRET measurements is limited due to 
several factors such as the inhomogeneity of the confocal volume and fluorescence 
quenching at high label densities. Improvements to the former have been suggested by 
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Murphy et al. through the use of Bayesian Inference [119], which led to the data analysis on 
population sizes and intramolecular distance being more robust than simple threshold-based 
analysis, especially in more complex datasets.  
Super-resolution techniques have been used to probe the seeding capacity of Aβ 
aggregates in addition to the morphology of aggregates in CSF [120,121]. By seeding 
fluorescently labelled Aβ40 with brain- and CSF-derived Aβ from AD and control patients it 
has been shown, using dSTORM, that seeding capacities and elongation rates were 
dependent on aggregate size [122].  
In order to perform label free imaging in vivo, there has been a surge in the development of 
fluorescence imaging probes with similar properties as ThT and Thioflavin S (ThS). Notably 
the class of oligothiophenes has been used to image Aβ aggregates in their pre-fibrillar and 
fibrillar state both in vitro and in vivo (Error! Reference source not found.) [123–125]. 
Interestingly, these dyes show different spectral footprints for the different amyloid 
topologies of Aβ and tau [126]. Similarly, the hydrophobicity reporter dye nile red has been 
used to spectrally super-resolve local hydrophobicity propensities of amyloid aggregates 
using sPAINT [74]. 
A different approach in understanding the molecular mechanisms of aggregation, and hence 
oligomer formation, is through the combination of high quality kinetic data and kinetic 
modelling. This work on Aβ has been pioneered by the Knowles and Linse groups. High 
purity recombinant monomeric Aβ42 has led to robust aggregation kinetics which has 
enabled the use of global fitting models to get insight into molecular mechanisms of the 
underlying processes [127–129]. 
An online modelling platform has been made available to investigate the effect of 
interactions of Aβ with, for example chaperones [130] or antibodies [131] and to model 
molecular mechanisms for other amyloid proteins [128]. This has shown that Aβ42 
aggregation is strongly dominated by secondary nucleation, and hence the presence of 
seeds has an autocatalytic effect on the aggregation process [15]. However, care needs to 
be taken when inferring in vivo mechanisms from in vitro models, as some of the effects may 
be compounded by cellular components, for example fibril seeding on the membrane.   
The application of the above mentioned advanced biophysical methods has led to insights 
into the molecular mechanisms underlying Aβ aggregation, and has given us insights into 
some structural features of the resulting soluble aggregates and amyloid fibrils. One of the 
main challenges is to link these molecular mechanisms and structural features to the 
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resulting neurological effects and finally to the clinical manifestation of the disease. The 
prolonged time-course of the disease and the low Aβ concentration in the extracellular space 
are of particular interest. In vitro, Aβ aggregation time-courses are usually studied over 
hours at concentrations that are orders of magnitudes higher of what is found in the CSF 
[132]. Furthermore, the interactions and interplay between different Aβ peptide isoforms and 
with other amyloid forming proteins have not been conclusively explored. The application of 
the techniques to describe here could allow the investigation of these problems at the atomic 
and molecular level and help understand the neurobiology of these diseases. 
4. Tau oligomers and filaments 
The aggregation of the microtubule associated protein tau into intracellular deposits plays a 
central role in the pathogenesis of AD and more than 20 other neurodegenerative disorders, 
collectively termed tauopathies [133]. Six different tau isoforms are produced in the adult 
human brain by alternative splicing of the MAPT (microtubule-associated protein tau) mRNA 
[11,134–138]. These have up to two N-terminal inserts and either three or four repeat 
regions (termed R1-R4) in the C-terminal half [139]. The vast majority of tauopathies are 
sporadic diseases with age being the main risk factor, however almost 80 pathogenic exonic 
missense and intronic silent mutations in the tau gene have been found in inherited cases of 
frontotemporal dementia [140–144]. These mutations tend to cluster around the repeat 
regions of tau which mediate microtubule binding and play an important role in the 
aggregation of tau as they form a large part of the core region of tau filaments [145,146]. 
Intronic mutations and some mutations in exon 10 interfere with the alternative splicing of 
tau mRNA, increasing the amount of 4 repeat tau over 3 repeat tau. Pathological tau is 
hyperphosphorylated and contains about 8 moles of phosphate per mole of protein 
compared to 2-3 moles per mole of protein in physiological tau [147,148].  
AFM and TEM have offered some important insights into the aggregation mechanism of tau. 
Notably, due to their high resolution, these techniques were successfully used to study small 
oligomeric tau species as well as ultrastructural properties of filamentous tau. Barrantes et 
al. used atomic force microscopy and spectroscopy to study tau aggregation in vitro in the 
absence of any inducers of aggregation. They found that tau rapidly forms heterogeneous 
granular oligomers with a height of 6-16 nm at room temperature, whereas fibrillar material 
was detectable only after a few months of incubation. Further, they showed using force 
spectroscopy that the interaction between tau monomers is relatively strong and required 
unbinding forces in the order of ligand-receptor or antigen-antibody interactions [149]. The 
formation of prefibrillar granular tau aggregates of similar size (15-25 nm) was also found in 
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two further studies, where tau aggregation was induced by the addition of heparin [150,151]. 
These granular aggregates formed at the end of the lag phase and appeared to be ThT-
active, indicating that these species are β-sheet rich aggregates. Interestingly, Maeda et al. 
could isolate such granular tau aggregates from AD patients as early as Braak stage I, 
before filamentous tau was detectable. The authors therefore suggested that these species 
represent early tau assemblies preceding mature filaments [150,152]. 
High resolution AFM and TEM were also used to assess the morphology and mechanical 
stability of tau fibrils formed in the presence of heparin. The high resolution of these 
techniques allowed the determination of the thickness and periodicity of tau fibrils and 
demonstrated their polymorphic nature [153]. In the same study it was also shown that 
hydrophobic surfaces or mechanical force by the AFM cantilever can lead to the 
fragmentation of tau fibrils into species with a similar morphology to the granular oligomers 
described above. This suggests that granular tau species could not only exist as a precursor 
of filaments but could also be produced by the fragmentation of fibrillar species. This 
highlights that care must be taken to identify and avoid artefacts when surface-dependent 
methods are employed to characterise amyloid species. In a second study by Wegmann et 
al., high resolution AFM was used in force-volume (FV) mode to study the orientation of the 
N- and C-terminal projection domains of full length tau [154]. FV-AFM is ideal to image 
biomolecules with high force sensitivity, and to simultaneously map their physicochemical 
properties at molecular resolution (1-2 nm) [155]. Using FV-AFM, the authors described the 
projection domains of tau, the “fuzzy coat”, as highly flexible polyelectrolyte brush 
surrounding the fibrillar core of tau. This coat is around 16 nm thick and mechanically up to 
four times softer than the fibrillar core [154]. Scanning transmission electron microscopy is 
able to provide mass per unit length measurements and has shown that tau filaments have a 
mass per length of 160 kDa (≈3.5 monomers) per nm for recombinant full length tau (2N4R 
Δ280K tau) and 130 kDa per nm for AD paired helical filaments (PHFs) [156].  
Notably, the advent of cryo-EM has recently allowed the first atomically-resolved (3.4-3.5 Å) 
visualisation and reconstruction of PHFs and straight filaments (SFs) extracted from a 
patient with AD [146]. This work confirmed that tau filaments are formed of two identical 
protofilaments with C-shaped subunits and that PHFs and SFs differ in the orientation and 
packing of these two protofilaments, as previously suggested based on lower resolution 
electron micrographs[157]. In their work, Fitzpatrick et al. provide, for the first time, full 
atomic maps for the tau filament core in PHFs and SFs (see Figure 5). This core region 
spans residues 306 to 378 of full length tau, corresponding to the repeat regions R3 and R4 
and a short stretch beyond R4 [78]. 
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Similar to Aβ, important mechanistic insights into the aggregation of tau have been gained 
by kinetic modelling. Whilst tau aggregation has been described by simple nucleation-
elongation models [158,159], the in vitro aggregation process of tau is complex as inducers 
of aggregation seem to act as ligands or allosteric regulators which bind transiently to tau 
[160,159,161–164]. This catalyses a conformational change of tau leading to the rapid 
formation of small nuclei. The lowered thermodynamic barrier of nucleation results in rapid 
aggregation kinetics even at very low protein concentrations, and without the presence of 
the classical lag time, a process which cannot necessarily be assigned to a canonical 
nucleation-polymerisation model [160]. Using confocal smFRET, Shammas et al. were able 
to track the evolution of transient K18 tau oligomers during aggregation, and demonstrated 
that the disease associated tau mutations ΔK280 and P301L lead to the formation of around 
50-fold more transient oligomers compared to wild-type tau during their aggregation (see 
Figure 6b) [165]. Similar trends were observed by Kumar et al., who used AFM and time 
correlated single photon counting (TCSPC) to study the oligomerisation of K18 tau [166]. 
Further, kinetic analysis of the oligomerisation process revealed that K18 tau aggregation, 
similar to αS [167], proceeds via monomeric assembly into small oligomers followed by a 
slow structural conversion step before fibril formation (Figure 6) [165]. Rate constants of the 
fundamental microscopic reaction steps could be determined, showing that the disease-
associated mutants have an increased nucleation rate compared to wild-type tau. As the 
primary nucleation of wild-type tau is comparatively slow and acts as a bottle-neck for 
aggregation, the authors predict that small amounts of seeds have a large effect on the 
amplification of wild-type tau aggregates in cells. In contrast, seeding is thought to play a 
less significant role for mutant tau with aggregation being dominated by primary nucleation 
[165]. This hypothesis is in agreement with a previous study in mice showing more efficient 
propagation of pathology by wild-type tau as compared to mutant tau [168]. Whilst a recent 
study provided some indirect evidence for secondary processes to occur during the 
aggregation of the short repeat domain construct K18 tau [169], the aggregation kinetics of 
full length tau appear not to be dominated by secondary processes such as secondary 
nucleation or fragmentation [159].  
The high sensitivity of smFRET for small oligomeric species has also been exploited to study 
the interaction of the molecular chaperone Hsp70 with different aggregate species of the 
K18 ∆K280 tau variant. This study showed that Hsp70 slows down the nucleation process of 
tau, stabilises oligomeric species and inhibits their growth into fibrils [170]. Similar findings 
were made in a second study, comparing the action of Hsp70 and a second chaperone, 
HspB1, on K18 and full length tau aggregation using FCS and NMR [171]. 
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Similar to TCCD and FRET, Giese and co-workers developed a method for the sensitive 
detection of protein aggregates. Using their technique, referred to as SIFT, the Giese lab 
identified the trivalent metal ions Al3+ and Fe3+ and organic solvents, such as dimethyl 
sulfoxide, as inducers of tau self-oligomerisation and co-aggregation with αS [172]. The 
latter was found to be moderately enhanced by tau phosphorylation [173]. Furthermore, they 
used FCS to study the effect of limited proteolysis of tau on its oligomerisation propensity. 
They showed that limited proteolysis by the extracellular matrix-metalloproteinase-9 (MMP-
9) leaves the repeat domain of tau largely intact, leading to the formation of an aggregation-
prone fragment of tau [174]. 
In a number of studies Rhoades and colleagues investigated interactions of tau with 
pathological and physiological targets. Using FCS, they show that lipid bilayers catalyse the 
aggregation of K18 tau by serving as a nucleation surface. Once a critical surface density is 
reached, tau aggregates into ThT-active species incorporating the lipid vesicles [175]. In a 
second study, Rhoades and co-workers systematically introduced FRET pairs distributed 
over the whole tau sequence to study its conformation in the absence and presence of an 
aggregation inducer, heparin [164]. In agreement with a previous bulk study by the 
Mandelkow lab [176], the N- and C-termini of monomeric tau were found to fold loosely over 
the microtubule repeat. Upon addition of heparin, tau undergoes a critical conformational 
change characterised by the loss of these long-range contacts and a contraction of the 
repeat region [164]. Furthermore, the distance between the different FRET pairs derived in 
the smFRET experiments described above served as constraints to model the 
conformational ensemble of tau during aggregation [177] It should be noted that whilst FRET 
provides valuable conformational information under physiological conditions, conformational 
artefacts may arise from the covalent attachment of the FRET dyes to the protein of interest.  
Another approach making use of organic fluorophores covalently attached to tau was 
chosen by Kaminski and Kaminski-Schierle. They demonstrated that the fluorescence 
lifetime of labelled aggregates changes with the appearance of β-sheet containing structures 
and that this change can be used to assess the aggregation state of amyloidogenic proteins 
in vitro and in vivo [178]. In a recent study by Michel et al., this principle was used to track 
the fate of monomeric K18 tau added to the extracellular medium of SH-SY5Y cells [179]. 
Importantly, in this study, 10% labelled K18 tau-AF488 and 90% unlabelled protein was used 
to reduce dye-dependent artefacts. Confocal TCSPC microscopy showed that tau was 
rapidly taken up into endosomal compartments and formed aggregates which appeared to 
seed endogenous tau [179]. Furthermore, two colour dSTORM imaging of the cell medium 
revealed that cells seeded with monomeric tau expelled fibrils into the cell medium 
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consisting of both endogenous and exogenously added tau. Interestingly, single fibrils 
contained multiple regions containing exogenous tau (“seed tau”) rather than one region 
comprising the “core seed”, which is not compatible with the simple elongation by monomer 
addition mechanism conventionally assumed for seeded aggregations. Fluorescence lifetime 
measurements were also used to assess the density of K18 tau fibril clusters as the 
fluorophores undergo strong self-quenching when in close proximity to each other [180]. 
Hereby it was also sufficient to have a fraction of the protein labelled with the organic 
fluorophore, requiring labelling ratios of 10% or higher. Surprisingly, whilst this assay 
appeared to be very efficient at detecting the formation of fibril clusters, fluorophores in 
single fibrils were not quenched and thus this method is not suitable to study the early 
aggregation steps such as the conversion of disordered oligomers to well-ordered fibrils 
[180]. Whilst the use of partially labelled tau samples, in which only a fraction of tau 
molecules is fluorescently labelled, leads to a decreased detection efficiency for smaller 
protein aggregates such as very small oligomeric species, it can be an efficient strategy to 
reduce the influence of the label on the aggregation behaviour. Generally, this approach can 
therefore be a good compromise when the amyloidogenic protein of interest is difficult to 
label in a non-perturbative way and ultrasensitive measurements are not crucial for the study 
to be conducted.  
Notably, for in vivo studies direct labelling is not applicable and immunostaining with labelled 
antibodies is commonly performed. Benda et al. demonstrated the use of STED microscopy 
to image immunostained tau aggregates in 50 µm AD brain sections. They achieved a 
spatial resolution of 77 nm, allowing the visualisation of single fibrils within NFTs. Also, small 
tau puncta and fibrillar fragments were observed in close proximity to the tangles. 
Furthermore, the resolution in the x-y plane could be maintained when z-stacks were 
recorded over 20 µm, allowing three-dimensional surface rendering of NFTs (although with 
confocal axial resolution). Ultrastructural features of filaments could not be resolved [181]. 
In summary, some important insights have been gained into the aggregation pathway of tau 
by advanced biophysical methods such as TEM and fluorescence microscopy. For tau, 
remaining challenges are a more comprehensive characterisation of small soluble species of 
the full length protein in vitro and in vivo, and the identification of mechanisms of toxicity 
conferred by such species. This field will benefit from improved labelling strategies, e.g. 
through more readily available site-specific labelling strategies or the development of 
nanobodies for tau, and new super-resolution techniques such as DNA-PAINT [73]. 
Furthermore, the ability to resolve aggregates at the atomic level by cryo-EM [75,76] will 
allow more profound insights into the ultrastructural features of tau filaments and will provide 
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important insights into the prion like character of tau, e.g. through the analysis of filaments 
found in other tauopathies. 
5. Alpha-synuclein and Parkinson’s disease 
αS is the major component of Lewy bodies found in PD and in other synucleinopathies [12]. 
It was one of the first described intrinsically disordered proteins, and has also been 
associated with amyloid plaques in AD [182]. In addition to its presence in Lewy bodies, the 
link between αS and PD is also evidenced by the duplication and triplication of the SNCA 
gene encoding αS leading to autosomal dominant forms of the disease [183,184], in addition 
to single residue missense mutations also causing early-onset forms of PD [185–190].  
The primary structure of αS can be divided into three regions: the positively charged N-
terminal region (residues 1-60), which contains imperfect repeats that resemble the 
apolipoprotein helical sequence and drive the acquisition of alpha-helix upon binding to 
membranes [191,192]; the central hydrophobic domain (residues 61-95), also called NAC 
(non-amyloid β-component), which is responsible for its aggregation and leads to the 
formation of beta-sheet during fibril formation [193,194]; and finally, the acidic C-terminal 
end (residues 96-140), which has a high proportion of negatively charged residues and 
prolines, contributes to protein solubility and has never been associated with α-helical or β-
sheet secondary structure [195]. αS has been described as a chameleon, as it is able to 
acquire different secondary structures depending on interaction with lipids and other proteins 
[196]. 
Despite the large majority of PD cases being sporadic [197], it is interesting to note that all 
disease-causing mutations are in the same N-terminal region of the protein just prior to the 
NAC region, indicating that mutations can influence the conformational landscape of αS and 
modulate its propensity to acquire secondary structure [198]. It has been shown that these 
mutations can indeed modulate in vitro and in vivo aggregation properties of αS [29,199–
203]. Some mutations are known to increase the aggregation tendency of αS, such as A53T 
and E46K [199,202,204], while others delay fibril-formation, for example A30P and G51D 
[29,203]. For the A30P mutation in particular, the hypothesis that αS forms a trapped 
population of oligomers that cannot go on to form fibrils has led to the belief that oligomers 
are responsible for inducing toxicity in PD [29]. However, as for other aggregating proteins, 
direct detection of these highly heterogeneous species has remained challenging. Alongside 
methods developed for studying other aggregating proteins, a number of techniques for 
characterising αS aggregates have also been established.  
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One of the earliest approaches was to find conditions that generate a large amount of 
oligomers. One such method involved incubating concentrated solutions of αS on ice, 
leading to the formation of annular oligomers analysed using TEM [205] (see Figure 7). 
Other protocols involve incubating αS at 37 oC [206,207] and inserting a size exclusion 
[208,209] or diafiltration step [210] to generate adequate amounts of oligomers for further 
studies. One such study [207] purified a kinetically-trapped oligomeric species that was 
accurately characterised using fluorescence, CD, AFM, DLS and cryo-EM. However, many 
types of such oligomers often do not proceed to form fibrils, but are instead trapped in an 
energy well for alternative aggregation/folding of αS, and so may not represent the real 
heterogeneity of αS oligomers [208,211–213]. However, this is not always the case, and in 
other cases, purified oligomers are able to go on to form fibrils [214,215]. Additionally, the 
type of oligomers formed is strongly dependent on the experimental conditions used [216]. 
Several additives have been used to boost the formation of these aggregates. Dopamine 
and fatty acids are often used to stabilise oligomers [211,215,217–221]. Oligomers obtained 
with these techniques have β-sheet content, in some cases α-helical content, are stable 
upon shifts in pH and temperature [222] and can interact with lipid membranes and cells 
[206,214,222–225]. These and other conditions have been extensively reviewed recently 
[226]. 
To the best of our knowledge, αS oligomers obtained from brain extracts have not been 
structurally characterised, meaning that there is no possibility to compare these oligomers 
with the ones formed in vitro. The end point of aggregation in vivo are amyloid fibrils, which 
are similar to those formed in vitro [18,19], thus suggesting that similar intermediate species 
may be formed throughout the processes. In an attempt to characterise some of the most 
elusive species, cross-linking techniques have been applied to capture the transient 
oligomers in vitro [227,228]. The resultant aggregates have been characterised in terms of 
their sizes, through use of DLS and SDS-PAGE gels; however, these cross-linked oligomers 
do not readily form fibrils, as their polypeptide chains cannot adapt or recruit further 
monomers for elongation [227]. Thus, it is not clear how well these findings represent native 
oligomers formed within the brain.  
Native mass spectrometry has also been used to investigate the sizes of αS oligomers [229]. 
However, this approach requires the oligomers to be dissolved in specific buffers, which may 
perturb their structures [230–232]. Data obtained from mass spectrometry describe the 
presence of different conformational states of monomer, and can detect the formation of 
dimers [230]. Moreover, drift-time analysis has been used to gain insights into oligomer 
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topology. Oligomers ranging in size from dimers to hexamers have been described [231]; 
however, larger oligomers cannot be analysed using such a method.  
As for Aβ and tau, fluorescence methods have successfully been employed for the sensitive 
and specific detection of intermolecular interactions. Structure-based non-covalent 
fluorescent probes have been developed to specifically detect the presence of oligomers, or 
pre-fibrillar species during aggregation [233,234]. Alternatively, fluorophores have been 
conjugated to specific sites of αS using maleimide chemistry on cysteine residues inserted 
by site-specific mutagenesis on the αS polypeptide chain [177,235,236]. These studies use 
properties such as pyrene excimer formation to be able to detect intermolecular contacts 
between αS monomer units. The presence of fluorescent probes on αS also allow FCS 
measurements to be performed, which enable estimation of size distributions of oligomers 
from their diffusion coefficients [177]. As is the case for tau, the labelling site for the 
fluorophores needs to be selected with care: it is important to ensure that the label does not 
introduce artefacts or affect oligomer formation. 
One of the first single-molecule fluorescence techniques applied to studying the aggregation 
of αS was SIFT [237–240]. As mentioned above, this method looks at the intensities of 
individual molecules and assigns the brighter bursts of fluorescence as originating from 
oligomeric species. Furthermore, photobleach step analysis allowed the determination of 
oligomer sizes in sub-stoichiometrically labelled αS. For this analysis a TIRF setup was used 
to detect single aggregates rather than a confocal setup as described for Aβ above [64]. The 
accurate counting of photobleaching steps is usually limited to there being less than ten 
fluorophores present; in any case, a purified oligomer containing 31 monomer units was 
identified. However, this method is biased for the detection of brighter species. Additionally, 
the analysis assumed only one size of oligomer, which may not have been the case.  
Through the introduction of a cysteine in the αS sequence at position 90, which is at the 
edge of the fibril-forming region, detailed analyses on the oligomer formation process have 
been achieved using the singe-molecule fluorescence methods TCCD and smFRET 
[35,59,241]. These experiments revealed the existence of two oligomeric populations, with 
different “compactness”, resistance to proteinase-K degradation and stability in low ionic 
strength buffers [58]. Furthermore, these techniques enabled a structural comparison of 
pathologically related mutants in solution, revealing subtle differences structural differences 
between the oligomers generated by mutants in comparison with the wild type protein 
[59,242]. The application of this method to aggregation kinetics run at different 
concentrations of αS permitted the inference of a kinetic model for αS oligomer formation in 
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vitro, enabling the calculation of conversion rates between the two different types of 
oligomers [243]. 
Unlabelled aggregates of αS have been directly observed using ThT and TIRF microscopy. 
This technique, referred to as Single Aggregate Visualisation by Enhancement (SAVE) 
imaging [51], has negated the need for a conjugated organic fluorophore, and so has 
enabled oligomers to be studied within biofluids. This has led to the finding that 
cerebrospinal fluid from PD patients contains a greater oligomer load than those samples 
from healthy controls (HC) (Figure 8). Additionally, sPAINT [74] has been used to look at 
both oligomers and fibrils of αS, and it was shown that the oligomers have a higher surface 
hydrophobicity than the fibrils, which may explain their greater toxicity.  
Despite the ability to observe oligomers in human biofluids, techniques still need to be 
developed and adjusted to observe native oligomers in cells or in vivo. Due to the low 
concentration and low stability of these species, oligomer visualisation within cells is 
challenging, and purification may affect their structure. So far, the large majority of detection 
methods for proteins in vivo is based on the use of antibodies [244,245]. A good number of 
techniques have been applied to detect αS self-interaction using complementation assays or 
proximity ligations assays [246–250] or confocal microscopy methods [251,252].  
6. Conclusion 
The rapid development of biophysical methods in the previous decades has clearly led to a 
greater understanding of some of the molecular processes in neurodegeneration. In 
particular, these studies were prevalent for proteins available in high amounts through 
synthetic or recombinant protein production. Both details on the atomic structures of amyloid 
fibrils, as well as their behaviour within cellular models have been revealed by these 
methods. Additionally, the kinetics of protein aggregation are now well understood, both in 
terms of the microscopic processes involved, and which of these dominate for the various 
proteins. These details enable the rapid assessment of inhibitory factors, and such methods 
may serve future roles as diagnostic tools, which are vitally needed if a therapeutic strategy 
is to be developed for neurodegenerative diseases.  
Despite the clear advantages of many advanced biophysical methods, their application 
requires specialist training and equipment and this significant investment of resources 
places a practical limit on the widespread use of these techniques. The development of new 
techniques and the ongoing improvement of existing techniques towards faster acquisition 
times and higher quality data output will allow the application of the techniques to a broader 
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range of problems. At the same time, biophysical studies need to become more 
comprehensive, for example by looking for common properties across different 
amyloidogenic proteins, but also through the use of more biologically relevant samples such 
as animal model or human post-mortem tissues. Both of these considerations call for a 
tighter collaboration between different labs in order to make pivotal advances in 
understanding neurodegenerative diseases. Taken together, the continuous improvement of 
existing biophysical tools such as super-resolution microscopy and the development of new 
techniques such as cryo-EM, as well as the improved access to a wide range of different 
samples, will yield new insights into the pathogenesis of neurodegenerative diseases and 
will pave the way for future therapies. 
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Box 1 Definitions of aggregate species 
 
Figure 1. Bulk techniques used to characterise the protein aggregation process. a) ThT 
fluorescence increase due to the aggregation of αS over time. b) Size distributions of 
monomeric, oligomeric and fibrillar populations of αS, measured by DLS. c) CD traces of αS 
monomers (blue trace), oligomers (red trace) and fibrils (green trace). (b) and (c) are 
adapted with permission from Horrocks et al. [51]. 
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Native monomer: the protein in its original native conformation. 
Misfolded monomer: a protein that has lost its native conformation to acquire one that is not 
functional and exposes hydrophobic patches. 
Oligomer: an assembly of misfolded protein that retains solubility, ranging in size from a dimer 
to fibrillar species.  
Nucleus: an aggregate from which monomer addition is thermodynamically favoured; it may 
coincide with any sized aggregate. 
Protofibrils: early fibrillar species. 
Prefibrillar species: all aggregated species less mature than fibrils, including oligomers, 
protofibrils and insoluble aggregates. 
Seed: small fibril unit from which monomers can bind for fibril elongation, bypassing oligomer 
formation. 
Mature Fibrils: fibrils that have complex architecture due to flanking of several protofibrils and 
involvement of other parts of the protein, not buried in the initial protofibril, which can interact 
by virtue of their proximity. 
Aggregate: Any non-native assembly of protein, ranging from dimer to mature fibril. 
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Figure 2. Schematic of (a) a confocal microscope setup and (b) an objective-based TIRF 
microscope. 
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Figure 3. TCCD and smFRET for the ultrasensitive detection of protein aggregates a) In 
TCCD, two colour excitation is used to excite molecules transiting the confocal volume. Only 
those which contain both dyes give rise to coincident bursts (yellow stars). b) In FRET based 
measurements, only one wavelength of light is used to excite the molecules. In molecules in 
which the two dyes are close enough for FRET to occur, there is a simultaneous burst in 
both channels. The dashed lines represent thresholds used to separate signal from noise. 
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Figure 4. High resolution fluorescence images and emission spectra of pFTAA bound to 
pathogenic hallmarks in AD. a,b) Fluorescence images showing an overview of the 
interaction between Aβ deposits (green), NFTs, and dystrophic neurites (yellow and red). c) 
Emission spectra of pFTAA bound to Aβ aggregates (green spectrum) or NFTs (red 
spectrum). d,e) High resolution fluorescence images showing the details of the distribution 
between Aβ deposits (green), NFTs, and dystrophic neurites (yellow and red). Selected Aβ 
deposits and NFTs are highlighted (green and red arrows, respectively) to indicate striking 
spatial co-localisation. Scale bar = 50 μm (a), 20 μm (b) and 10 μm (d and e). Figure 
adapted from Aslund et al. [124]. 
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Figure 5. AD tau filaments at atomic resolution. a,b) Cryo-EM reconstructions of PHFs (blue) 
and SFs (green). c,d) Cryo-EM density and atomic models of PHFs (c) and SFs (d). 
Overviews of the helical reconstructions (left) show the orientation of the cross-sectional 
densities (right). Sharpened, high-resolution maps are shown in blue (PHFs) and green 
(SFs). Red arrows indicate additional densities in contact with K317 and K321. 
Unsharpened, 4.5 Å low-pass filtered density is shown in grey. Figure adapted from 
Fitzpatrick et al. [78].  
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Figure 6 Kinetic analysis of single-molecule data identifies conversion step of tau during 
aggregation. a) Coarse-grained on-pathway conversion model of tau oligomers. Initial 
formation of non-growth-competent oligomeric species x(t), of average length xa(t), occurs 
via a reaction of order nc in monomer concentration m(t). Formation of fibrils f(t), of average 
length fa(t), then proceeds via addition of monomer units in a reaction of first order in m(t). 
Rate constants (k) for these processes and their corresponding reverse reactions are 
labelled. b) Oligomeric and (deduced) fibrillar concentrations during the aggregation of K18-
ΔK280 tau. Best fits for coarse-grained nucleation–conversion–polymerisation description for 
K18-ΔK280 are shown as solid lines. Figure adapted from Shammas et al. [165]. 
 
 
Figure 7 TEM images of oligomers. a) Annular oligomers described for the first time by 
Lashuel et al. [205] formed by dissolving lyophilised αS in PBS at a concentration ranging 
from 300-700 µM and incubating on ice for 30-60 min. Oligomers were then filtered through 
0.22 µm filters and separated from monomers by gel filtration. Scale bar is 50 nm. b) 
Spherical oligomers as observed by Ehrnhoefer et al. [213]. 100 µM αS was incubated in the 
presence of N-epigallocatechin gallate (1:10) and incubated in TBS buffer on a rotary shaker 
a b
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(conditions favouring aggregation) at 37°C. Oligomers were separated from monomers and 
other aggregates by gel filtration. Scale bar is 100 nm. Adapted from Ehrnhoefer et al. [213] 
 
 
 
Figure 8 SAVE imaging of αS aggregates in cerebrospinal fluid. a) SAVE image from a PD 
sample. Green circles show detected oligomers. Scale bar is 5 μm in the main image, and 
500 nm in the zoomed inset. b) Mean number of oligomers detected for each CSF. 
Horizontal lines show the mean counts for PD and HC samples. c) Box plots of total αS 
concentrations from ELISA measurement. Even though the total αS load is not significantly 
different between the PD and HC samples, SAVE imaging detects significantly more 
aggregates in the PD samples. Figure adapted from Horrocks et al. [51].  
 
 
Table 1 Overview of possible techniques for the measurement of various aggregated 
proteins and their typical application spectrum. A green tick means that the indicated 
technique is typically viable within the given parameters of the sample whereas the red 
crossed circle indicates it is not. This table is by no means exhaustive and under certain 
circumstances measurements are still viable outside the indicated ranges and applications. 
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It should give however a quick visual aid to find the right biophysical technique for specific 
applications observing amyloid proteins. 
 
